Back to Search Start Over

Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma.

Authors :
Zhang, Zhao
Ma, Lijie
Goswami, Shyamal
Ma, Jiaqiang
Zheng, Bohao
Duan, Meng
Liu, Longzi
Zhang, Lijun
Shi, Jieyi
Dong, Liangqing
Sun, Yumeng
Tian, Lingyu
Gao, Qiang
Zhang, Xiaoming
Source :
OncoImmunology. 2019, Vol. 8 Issue 4, p1-1. 1p.
Publication Year :
2019

Abstract

As a major cellular component in tumor microenvironment, the distribution, frequency, and prognostic significance of infiltrating B cell subsets in hepatocellular carcinoma (HCC) remain controversial. Using tyramide signal amplification (TSA) based fluorescent multiplexed immunohistochemistry in situ, we evaluated the distribution and frequency of B cell subsets in two independent HCC cohorts (n = 619). The results were further confirmed by flow cytometry. Correlations of B cell subsets with clinicopathologic features and patient prognosis were analyzed. Five B cell subsets were defined by multiplexed immunohistochemistry and each subset was clearly separated by t-SNE dimension reduction analysis. Notably, the densities of all B cell subsets were significantly decreased in the tumor. The frequency of plasma cells within B cells was most abundant in the tumor. In training cohort (n = 258), high densities of tumor-infiltrating CD20+ B cells, naive B cells, IgM+ memory B cells, CD27− isotype-switched memory B cells, and plasma cells were associated with superior survival. Multivariate analysis further identified CD20+ B cells, naive B cells, and CD27− isotype-switched memory B cells as independent prognosticators for survival. Unsupervised cluster analysis confirmed increased B cell subsets harbored superior survival. In addition, high density of B cells was correlated with smaller tumor size and well differentiation. The results were validated in the independent cohort of 361 HCC patients. Intratumor infiltration of B cells is significantly impaired during HCC progression. High densities of tumor-infiltrating B cells imply a better clinical outcome. Therapies designed to target B cells may be a novel strategy in HCC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
21624011
Volume :
8
Issue :
4
Database :
Academic Search Index
Journal :
OncoImmunology
Publication Type :
Academic Journal
Accession number :
135500998
Full Text :
https://doi.org/10.1080/2162402X.2019.1571388